SciSparc Ltd.
SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement wā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.70
Price-0.67%
-$0.04
1Y
Price
Market Cap
$387.232k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+113.2%
EBITDA Margin-721.8%
Net Profit Margin-576.2%
Free Cash Flow Margin+113.2%
EBITDA Margin-721.8%
Net Profit Margin-576.2%
Free Cash Flow MarginRevenue
$856k
+65.5%
1y CAGR+41.5%
3y CAGR+37.7%
5y CAGREarnings
-$12.179m
-193.8%
1y CAGR-104.7%
3y CAGR-64.7%
5y CAGREPS
-$882.64
-2281.6%
1y CAGR-726.8%
3y CAGR-525.1%
5y CAGRBook Value
$5.147m
$7.622m
Assets$2.475m
Liabilities$366k
DebtDebt to Assets
4.8%
-
Debt to EBITDAFree Cash Flow
-$4.137m
-81.0%
1y CAGR-4.6%
3y CAGR-41.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company